Q1 EPS Forecast for Phibro Animal Health Raised by Analyst

Key Points

• Zacks Research has raised its Q1 2026 earnings estimate for Phibro Animal Health Corporation (NASDAQ: PAHC) to $0.62 per share, significantly up from a prior estimate of $0.33.
• Phibro Animal Health recently announced a quarterly dividend of $0.12 per share, representing an annual yield of 1.2% and a payout ratio of 40.68%.
• The stock has received a mix of ratings from analysts, with one "Buy," four "Hold," and two "Sell" ratings, and a current consensus target price of $28.40.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Research analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for Phibro Animal Health in a report issued on Wednesday, September 10th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.62 per share for the quarter, up from their prior estimate of $0.33. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health's Q4 2026 earnings at $0.68 EPS and FY2026 earnings at $2.67 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The company had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

A number of other research firms have also recently commented on PAHC. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective for the company in a research report on Monday, June 16th. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research report on Thursday, August 28th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Finally, Bank of America upped their target price on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a report on Friday, August 29th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Phibro Animal Health presently has an average rating of "Reduce" and an average target price of $28.40.

Phibro Animal Health Stock Performance

NASDAQ:PAHC traded down $1.57 during trading hours on Friday, reaching $39.62. The company had a trading volume of 238,815 shares, compared to its average volume of 385,401. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $41.57. The firm has a market cap of $1.61 billion, a PE ratio of 33.58, a price-to-earnings-growth ratio of 1.18 and a beta of 0.88. The business's 50 day moving average price is $31.98 and its 200-day moving average price is $25.55. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Wednesday, September 3rd. Phibro Animal Health's dividend payout ratio (DPR) is currently 40.68%.

Insider Buying and Selling at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 14,080 shares of Phibro Animal Health stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $40.33, for a total value of $567,846.40. Following the transaction, the chief executive officer directly owned 45,400 shares in the company, valued at approximately $1,830,982. This trade represents a 23.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 50.07% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PAHC. Price T Rowe Associates Inc. MD grew its stake in shares of Phibro Animal Health by 9.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,668 shares of the company's stock valued at $372,000 after purchasing an additional 1,565 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Phibro Animal Health by 7.2% in the 4th quarter. Northern Trust Corp now owns 245,110 shares of the company's stock valued at $5,147,000 after buying an additional 16,421 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Phibro Animal Health by 31.2% in the 4th quarter. Ameriprise Financial Inc. now owns 90,782 shares of the company's stock valued at $1,906,000 after buying an additional 21,576 shares during the period. Cetera Investment Advisers acquired a new stake in shares of Phibro Animal Health in the 4th quarter valued at approximately $204,000. Finally, Deutsche Bank AG lifted its holdings in shares of Phibro Animal Health by 90.8% in the 4th quarter. Deutsche Bank AG now owns 16,873 shares of the company's stock valued at $354,000 after buying an additional 8,032 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.